Imatinib and norimatinib therapeutic monitoring using dried blood spots: Analytical and clinical validation, and performance comparison of volumetric collection devices使用干血斑进行伊马替尼和诺利替尼治疗药物监测:分析验证与临床验证,以及体积收集装置的性能比较JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCESIF2.82025-04-010PRE
Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case seriesFRONTIERS IN IMMUNOLOGYIF5.92024-10-091OAAI
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+HER2-metastatic breast cancerBIOMEDICINE & PHARMACOTHERAPYIF7.52023-11-014OAAI
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposureBIOMEDICINE & PHARMACOTHERAPYIF7.52023-08-0115OAAI
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug MonitoringPHARMACEUTICSIF5.52023-05-1812OAAI
A fast and validated LC-MS/MS method to quantify lenvatinib in dried blood spotJOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSISIF3.12023-03-014PRE
A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinomaJOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSISIF3.12020-08-0114PREAI